Compare Charles River Laboratories Intl. Inc (CRL) vs iShares 7-10 Year Treasury Bond ETF (IEF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $285.8 (market cap $13.46B), while iShares 7-10 Year Treasury Bond ETF trades at $93.05. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| CRL | IEF | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | — |
52-Week High | $282.00 | $97.99 |
52-Week Low | $145.57 | $92.76 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
IEF, an ETF tracking 7-10 year US Treasury bonds, trades at $93.13, up 0.4% on the day. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators are neutral. Recent news highlights institutional buying interest amid rising Treasury yields and inflation concerns. The ETF pays regular dividends, with recent distributions around $0.31-$0.32 per share.
The outlook for IEF hinges on interest rate trends and inflation data. Higher yields may pressure prices, but institutional accumulation suggests long-term confidence. Key risks include Fed policy shifts and geopolitical tensions affecting oil prices and bond markets. Investors should weigh yield attractiveness against duration risk in a volatile rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →
